The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.
 
Julie Nicole Graff
Honoraria - Astellas Medivation; Bayer; Bayer; Bayer; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology; Sanofi; Valeant/Dendreon
Consulting or Advisory Role - Exelixis
Speakers' Bureau - i3 CME
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Merck Sharp & Dohme; Merck Sharp & Dohme; Sanofi
 
Joseph Burgents
Employment - Array BioPharma; Array BioPharma (I); AstraZeneca; AstraZeneca (I); Merck; Merck (I); Merrimack; Merrimack (I)
Stock and Other Ownership Interests - Array BioPharma; Array BioPharma (I); AstraZeneca; AstraZeneca (I); Merck; Merck (I); Merrimack; Merrimack (I)
 
Li Wen Liang
Employment - MSD
Stock and Other Ownership Interests - MSD
 
Arnulf Stenzl
Consulting or Advisory Role - Alere; Bristol-Myers Squibb; Ipsen; Janssen; Roche; Steba Biotech
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Karl Storz; Medivation
Patents, Royalties, Other Intellectual Property - 2018/6579 Gene-expression signature for subtype and prognostic prediction of renal cell carcinoma; AT00/0001:C-Trap, implantable device to treat urinary incontinence; Patent A290/99 Implantable incontinence device
Expert Testimony - GBA Pharma
Travel, Accommodations, Expenses - CureVac; Ferring; Ipsen; Janssen; Sanofi/Aventis